Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mian Xi

Showing results (71-80 of 108) with videos related to

Pageof 11
Sort By:
Medical Oncology (Northwood, London, England)|December 15, 2011
Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinomaLei Zhao, Li-Ru He, Rui Zhang, et al.
Chinese Journal of Cancer|September 16, 2015
Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinomaLi-Ling Luo, Lei Zhao, Mian Xi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2007
Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CTMian Xi, Meng-Zhong Liu, Xiao-Wu Deng, et al.
AI Zheng = Aizheng = Chinese Journal of Cancer|January 16, 2007
[Internal target volume definition using four-dimensional CT and dosimetric evaluation for hepatocellular carcinoma]Mian Xi, Meng-Zhong Liu, Xiao-Wu Deng, et al.
Oncogene|March 12, 2020
TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZSha Zhou, Shiliang Liu, Chuyong Lin, et al.
British Journal of Cancer|December 19, 2025
Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysisShiliang Liu, Yujin Xu, Xufeng Guo, et al.
The Oncologist|November 25, 2024
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trialShiliang Liu, Baoqing Chen, Yujia Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II TrialFang Shi, Haohua Wang, Yongjing Yang, et al.
Oncotarget|May 18, 2016
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysisPeng Zhang, Mian Xi, Qiao-Qiao Li, et al.
Cancer Medicine|April 18, 2022
Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinomaYu-Xian Yang, Yu-Zhen Zheng, Tian-Tian Gao, et al.
Pageof 11

Showing results (71-80 of 108) with videos related to

Sort By:
Pageof 11
Medical Oncology (Northwood, London, England)|December 15, 2011
Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinomaLei Zhao, Li-Ru He, Rui Zhang, et al.
Chinese Journal of Cancer|September 16, 2015
Association of insulin-like growth factor-binding protein-3 with radiotherapy response and prognosis of esophageal squamous cell carcinomaLi-Ling Luo, Lei Zhao, Mian Xi, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 31, 2007
Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CTMian Xi, Meng-Zhong Liu, Xiao-Wu Deng, et al.
AI Zheng = Aizheng = Chinese Journal of Cancer|January 16, 2007
[Internal target volume definition using four-dimensional CT and dosimetric evaluation for hepatocellular carcinoma]Mian Xi, Meng-Zhong Liu, Xiao-Wu Deng, et al.
Oncogene|March 12, 2020
TRIB3 confers radiotherapy resistance in esophageal squamous cell carcinoma by stabilizing TAZSha Zhou, Shiliang Liu, Chuyong Lin, et al.
British Journal of Cancer|December 19, 2025
Integrating lymphovascular invasion and ypTNM staging system for esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy and surgery: a multi-institutional analysisShiliang Liu, Yujin Xu, Xufeng Guo, et al.
The Oncologist|November 25, 2024
Induction chemotherapy plus chemoradiotherapy in esophageal cancer: long-term results and exploratory analyses of a randomized controlled trialShiliang Liu, Baoqing Chen, Yujia Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Continuation of First-Line Systemic Therapy with Progression-Directed Radiotherapy in Patients with Oligoprogressive Hepatocellular Carcinoma: A Multicenter, Single-Arm, Phase II TrialFang Shi, Haohua Wang, Yongjing Yang, et al.
Oncotarget|May 18, 2016
Concurrent cisplatin and 5-fluorouracil versus concurrent cisplatin and docetaxel with radiotherapy for esophageal squamous cell carcinoma: a propensity score-matched analysisPeng Zhang, Mian Xi, Qiao-Qiao Li, et al.
Cancer Medicine|April 18, 2022
Progression-free survival at 3 years is a reliable surrogate for 5-year overall survival for patients suffering from locally advanced esophageal squamous cell carcinomaYu-Xian Yang, Yu-Zhen Zheng, Tian-Tian Gao, et al.
Pageof 11